PURPOSE: The serotonin 2A (5-HT(2A)) receptor is of interest in several psychiatric and neurological diseases. In the present study we investigated the longitudinal stability of 5-HT(2A) receptors and the stability of the quantification procedure in the elderly in order to be able to study elderly patients with neuropsychiatric diseases on a longitudinal basis. METHODS: [(18)F]-Altanserin PET was used to quantify 5-HT(2A) receptors in 12 healthy elderly individuals at baseline and at 2 years in six volumes of interest. A bolus/infusion protocol was used to achieve the binding potential, BP(P). The reproducibility as assessed in terms of variability and the reliability as assessed in terms of intraclass correlation coefficient (ICC) were used to compare inter- and intraobserver stability and to evaluate the effects of increasing complexity of partial volume (PV) corrections. We also compared the stability of our measurements over 2 years with the stability of data from an earlier study with 2-week test-retest measurements. RESULTS: BP(P) was unaltered at follow-up without the use of PV correction and when applying two-tissue PV correction, test-retest reproducibility was 12-15% and reliability 0.45-0.67 in the large bilateral regions such as the parietal, temporal, occipital and frontal cortices, while orbitofrontal and anterior cingulate cortical regions were less stable. The use of PV correction decreased the variability but also decreased the between-subject variation, thereby worsening the reliability. CONCLUSION: In healthy elderly individuals, brain 5-HT(2A) receptor binding remains stable over 2 years, and acceptable reproducibility and reliability in larger regions and high intra- and interobserver stability allow the use of [(18)F]-altanserin in longitudinal studies of patients with neuropsychiatric disorders.
PURPOSE: The serotonin 2A (5-HT(2A)) receptor is of interest in several psychiatric and neurological diseases. In the present study we investigated the longitudinal stability of 5-HT(2A) receptors and the stability of the quantification procedure in the elderly in order to be able to study elderly patients with neuropsychiatric diseases on a longitudinal basis. METHODS: [(18)F]-Altanserin PET was used to quantify 5-HT(2A) receptors in 12 healthy elderly individuals at baseline and at 2 years in six volumes of interest. A bolus/infusion protocol was used to achieve the binding potential, BP(P). The reproducibility as assessed in terms of variability and the reliability as assessed in terms of intraclass correlation coefficient (ICC) were used to compare inter- and intraobserver stability and to evaluate the effects of increasing complexity of partial volume (PV) corrections. We also compared the stability of our measurements over 2 years with the stability of data from an earlier study with 2-week test-retest measurements. RESULTS: BP(P) was unaltered at follow-up without the use of PV correction and when applying two-tissue PV correction, test-retest reproducibility was 12-15% and reliability 0.45-0.67 in the large bilateral regions such as the parietal, temporal, occipital and frontal cortices, while orbitofrontal and anterior cingulate cortical regions were less stable. The use of PV correction decreased the variability but also decreased the between-subject variation, thereby worsening the reliability. CONCLUSION: In healthy elderly individuals, brain 5-HT(2A) receptor binding remains stable over 2 years, and acceptable reproducibility and reliability in larger regions and high intra- and interobserver stability allow the use of [(18)F]-altanserin in longitudinal studies of patients with neuropsychiatric disorders.
Authors: C C Meltzer; J C Price; C A Mathis; P J Greer; M N Cantwell; P R Houck; B H Mulsant; D Ben-Eliezer; B Lopresti; S T DeKosky; C F Reynolds Journal: Am J Psychiatry Date: 1999-12 Impact factor: 18.112
Authors: Claus Svarer; Karine Madsen; Steen G Hasselbalch; Lars H Pinborg; Steven Haugbøl; Vibe G Frøkjaer; Søren Holm; Olaf B Paulson; Gitte M Knudsen Journal: Neuroimage Date: 2004-12-09 Impact factor: 6.556
Authors: G S Smith; J C Price; B J Lopresti; Y Huang; N Simpson; D Holt; N S Mason; C C Meltzer; R A Sweet; T Nichols; D Sashin; C A Mathis Journal: Synapse Date: 1998-12 Impact factor: 2.562
Authors: Lars H Pinborg; Haroon Arfan; Steven Haugbol; Kirsten Ohm Kyvik; Jacob V B Hjelmborg; Claus Svarer; Vibe G Frokjaer; Olaf B Paulson; Soren Holm; Gitte M Knudsen Journal: Neuroimage Date: 2007-09-21 Impact factor: 6.556
Authors: S G Hasselbalch; K Madsen; C Svarer; L H Pinborg; S Holm; O B Paulson; G Waldemar; G M Knudsen Journal: Neurobiol Aging Date: 2007-06-04 Impact factor: 4.673
Authors: Lars H Pinborg; Karen H Adams; Claus Svarer; Søren Holm; Steen G Hasselbalch; Steven Haugbøl; Jacob Madsen; Gitte M Knudsen Journal: J Cereb Blood Flow Metab Date: 2003-08 Impact factor: 6.200
Authors: Steven Haugbøl; Lars H Pinborg; Haroon M Arfan; Vibe M Frøkjaer; Jacob Madsen; Tim B Dyrby; Claus Svarer; Gitte M Knudsen Journal: Eur J Nucl Med Mol Imaging Date: 2006-12-29 Impact factor: 10.057
Authors: Alexander Hammers; Marie-Claude Asselin; Federico E Turkheimer; Rainer Hinz; Safiye Osman; Gary Hotton; David J Brooks; John S Duncan; Matthias J Koepp Journal: Neuroimage Date: 2007-07-24 Impact factor: 6.556
Authors: Jacob M Hooker; Sung Won Kim; Achim T Reibel; David Alexoff; Youwen Xu; Colleen Shea Journal: Bioorg Med Chem Date: 2010-04-20 Impact factor: 3.641
Authors: Louise M Paterson; Birgitte R Kornum; David J Nutt; Victor W Pike; Gitte M Knudsen Journal: Med Res Rev Date: 2011-06-14 Impact factor: 12.944
Authors: Julian Macoveanu; Bettina Hornboll; Rebecca Elliott; David Erritzoe; Olaf B Paulson; Hartwig Siebner; Gitte M Knudsen; James B Rowe Journal: Neuropsychopharmacology Date: 2012-12-19 Impact factor: 7.853
Authors: Marie Spies; Arafat Nasser; Brice Ozenne; Peter S Jensen; Gitte M Knudsen; Patrick M Fisher Journal: Hum Brain Mapp Date: 2020-07-22 Impact factor: 5.038